

LISTING AND AMENDMENT OF THE CLAIMS:

1. – 74. (Canceled)

75. (Currently amended) A method of activating inactivated mtALDH in a patient who has received nitroglycerin therapy and has become nitroglycerin tolerant so the patient no longer responds to nitroglycerin comprising administering inactivated mtALDH activating effective amount of agent selected from the group consisting of dihydrolipoic acid, dithiothreitol and tris(2-carboxyethylphosphine).

76. (Previously presented) The method of claim 75 where the patient is affected with a disorder selected from the group consisting of angina, restenosis, heart failure, portal hypertension, asthma and rectal spasm.

77. (Previously presented) The method of claim 76 where the patient is affected with angina.

78. (Previously presented) The method of claim 77 where the agent is dihydrolipoic acid.

79. (Previously presented) The method of claim 77 where the agent is dithiothreitol.

80. (Previously presented) The method of claim 77 where the agent is tris(2-carboxyethylphosphine).

81. (Previously presented) The method of claim 75 where the agent is dihydrolipoic acid.

82. (Previously presented) The method of claim 75 where the agent is dithiothreitol.

83. (Previously presented) The method of claim 75 where the agent is tris(2-carboxyethylphosphine).

84. (New) A method for restoring clinical sensitivity to nitroglycerin to a patient who has lost sensitivity to nitroglycerin so that the patient no longer responds to nitroglycerin comprising administering to the patient a nitroglycerin sensitivity restoring amount of dihydrolipoic acid, dithiothreitol or tris(2-carboxyethylphosphine).